The stock of Spero Therapeutics Inc. (NASDAQ:SPRO) increased by $0.05 on Wednesday to $1.42, up 4.01 percent. The last five days have seen an average of 722,982 shares of common stock traded. 10 times new highs were reached in the current year, with a fall of -$0.2900. The average number of shares traded over the last 20 days was 393,561, while the average volume over the last 50 days totaled 364,514.
SPRO stock dropped -6.25% since last month. On 08/28/23, the company’s shares reached a one-month low of $1.2400. The stock touched a high of $3.18 on 01/17/23, after rallying from a low of $0.71 in 52 weeks. The price of SPRO stock has declined by -17.63% or -$0.2900 this year, reaching a new high 10 times. Still, the stock price is down -55.19% from the 52-week high.
Insider Transactions
SPRO stock investors should be aware that Spero Therapeutics Inc. (SPRO) stock had its last reported insider trading activity 208 days ago on Feb 03. On Feb 03, CEO and President Mahadevia Ankit sold 12,286 shares at $1.81 each. This transaction resulted in the insider making $22,238. On Feb 02, Shukla Sath sold 9,504 shares at a price of US$1.83. After the transaction, the insider now owns 312,517 shares. Chief Legal Officer JOSEPH TAMARA L had earlier sold 3,394 shares on Feb 02 for $1.86 a share. The transaction was completed for $6,313.
Valuation Metrics
Beta for the stock is 0.90. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.41, the price-to-book (PB) ratio of 1.37, and the price-to-cash flow ratio of 6.36.
Company paid $0.0150 per share in dividends, remained unchanged from $0.0150 last year.
Financial Health
For the three months ended June 29, Spero Therapeutics Inc.’s quick ratio was 5.10, while its current ratio was 5.10, indicating its ability to pay off its debt. Spero Therapeutics Inc.’s EBITDA margin for the year ended June 29 was -69.89%, whereas its operating margin stood at -24.10% for the same period. Based on annual data, it had gross profit of $95.71 million and revenue of $53.51 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. SPRO’s return on assets (ROA) during the last 12 months has been -10.10%. There was a -60.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -17.70%.
Earnings Surprise
According to Spero Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $2.72 million, while revenues rose by 26.84% to $2.07 million. It was predicted that Spero Therapeutics Inc.’s quarterly earnings would be -$0.23, but it ended up being -$0.34, beating the consensus by 32.40%. EBITDA was -$12.78 million for the quarter. At the end of Spero Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 44.1 million, while its total debt was $6.11 million. Equity owned by shareholders amounts to $52.7 million.
Technical Picture
Here’s a quick look at Spero Therapeutics Inc.’s (SPRO) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 62.88%, suggesting the stock is Neutral, with a 57.40% historical volatility rate.
The stochastic %K and %D were 36.48% and 22.18% respectively, while the average true range (ATR) was 0.1001. Based on the 14-day stochastic reading of 47.62%, the RSI (14) reading is 55.43%. On the 9-day MACD Oscillator, the stock is at 0.0411, and the 14-day reading is at 0.0281.
Analyst Ratings
In its most recent analyst report, Evercore ISI raised its rating on Spero Therapeutics Inc. (NASDAQ: SPRO) to an Outperform. Prior to this, analysts firm rated the stock as an In-line. Analysts have assigned Spero Therapeutics Inc. (SPRO) an Overweight rating. SPRO is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is SPRO’s price target for the next 12 months?
The current consensus forecast for the stock is between $5.00 and $8.00, with a median target price of $7.00. In analyzing these forecasts, the average price target given by analysts for Spero Therapeutics Inc. (SPRO) is $6.67.
